NCT07619508Completed
Tirzepatide vs Semaglutide in Individuals at Cardiovascular Risk But Without Diabetes.
Comparative Effectiveness of Tirzepatide and Semaglutide in Patients at Cardiovascular Risk With Overweight or Obesity But Without Diabetes
Source: ClinicalTrials.gov · Last updated 9 Jul 2026
Brief summary (registry, in English)
Investigators are building an empirical evidence base for real world data through large-scale emulation of randomized controlled trials. The investigators' goal is to understand for what types of clinical questions real world data analyses can be conducted with confidence and how to implement such studies.
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 100000 (actual)
- First submitted
- 23 May 2026
- Start date
- 10 Feb 2026
- Primary completion date
- 1 Jun 2026
- Lead sponsor
- Brigham and Women's Hospital
- Diseases
- Obesity
- NCT number
- NCT07619508
What you commit to
- Study type: Observational
- Participants enrolled: 100000
- From 10 Feb 2026 to the primary completion date, 1 Jun 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Prior use of pramlintide or any GLP-1-RA, except tirzepatide or semaglutide
Other illness
- MEN syndrome type 2
- Malignancy
- Type 1 diabetes
- Type 2 diabetes
- Secondary diabetes
- End-stage renal disease or dialysis
- History of bariatric surgery
Other
- Medullary thyroid carcinoma
- Pregnancy
- Cardiovascular event or intervention in the last 7 days
Who the study is looking for
- Men or women aged 18 years or older
- History of myocardial infarction, stroke, any surgical or percutaneous revascularization procedure
- Use of antihypertensive or lipid-lowering drugs
- Coronary, carotid, or peripheral artery disease
- BMI greater than or equal to 25.0 mg/m2
Criteria the registry did not label
- Study period:
- Optum: Eligible cohort entry period between May 13, 2022 to November 30, 2025. MarketScan: Eligible cohort entry period between May 13, 2022 to September 30, 2023.
- Medicare: Eligible cohort entry period between May 13, 2022 to September 30, 2024.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Brigham and Women's Hospital Coordinator of this site? Confirm its status | Boston | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.